<div id="readability-page-1"><p>Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) dropped 7.4% during trading on Tuesday following a dissappointing earnings announcement. The stock traded as low as $14.23 and last traded at $14.34. 1,069,083 shares were traded  during mid-day trading, a decline of 53% from the average daily volume of 2,257,449 shares. The stock had previously closed at $15.48.</p><div><p><span></span><span>Get <strong>Syndax Pharmaceuticals</strong> alerts:</span></p></div><p>The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The firm had revenue of $7.68 million for the quarter, compared to analysts' expectations of $86.32 million. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of brokerages have recently weighed in on SNDX. StockNews.com lowered shares of Syndax Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, November 23rd. Citigroup boosted their target price on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, November 19th. Scotiabank reduced their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a &#34;sector perform&#34; rating on the stock in a research report on Wednesday, January 8th. JPMorgan Chase &amp; Co. raised their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group upped their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, November 7th. One analyst  has rated the stock with a sell rating, one  has assigned  a hold rating and nine have issued  a buy rating to the company. According to MarketBeat, Syndax Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $36.20.</p><p><b>Get Our Latest Research Report on SNDX</b></p><h2>Insiders Place Their Bets</h2><p>In other news, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the sale, the chief executive officer now directly owns 300,121 shares of the company's stock, valued at approximately $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Neil Gallagher sold 4,618 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the transaction, the insider now owns 85,095 shares in the company, valued at approximately $1,318,972.50. The trade was a 5.15 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,683 shares of company stock worth $336,087. Company insiders own  4.10% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp raised its position in  Syndax Pharmaceuticals by 4.1% in the third quarter. State Street Corp now owns 3,770,826 shares of the company's stock worth $72,588,000 after acquiring an additional 148,491 shares during the period.  Soleus Capital Management L.P. grew its holdings in  Syndax Pharmaceuticals by 128.4% during the fourth quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock valued at $32,944,000 after purchasing an additional 1,401,016 shares during the period.  Assenagon Asset Management S.A. increased its position in  Syndax Pharmaceuticals by 343.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company's stock worth $27,292,000 after buying an additional 1,598,428 shares in the last quarter.  Geode Capital Management LLC raised its stake in shares of  Syndax Pharmaceuticals by 3.5% in the third quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company's stock worth $38,066,000 after buying an additional 66,459 shares during the period.  Finally, Franklin Resources Inc. lifted its position in shares of  Syndax Pharmaceuticals by 13.4% during the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company's stock valued at $34,948,000 after buying an additional 208,043 shares in the last quarter. </p><h2>Syndax Pharmaceuticals Stock Performance</h2><p>The company has a market capitalization of $1.23 billion, a PE ratio of -3.97 and a beta of 0.90. The company's fifty day moving average is $14.23 and its 200-day moving average is $16.75. </p><h2>About Syndax Pharmaceuticals</h2> (Get Free Report)<p>Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Syndax Pharmaceuticals</li><li>What Investors Need to Know to Beat the Market</li><li>Tesla  Stock: Finding a Bottom May Take Time</li><li>The How And Why of Investing in Oil Stocks</li><li>Duolingo: This Beaten-Down Stock Is About to Rally 38%</li><li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li><li>Zoom Stock: Leading the Video Market After Skype’s Exit</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?</h2><p>Before you consider Syndax Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.</p><p>While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SNDX

<p>Syndax Pharmaceuticals (NASDAQ:SNDX) shares fell 7.4% to $14.34 after disappointing earnings, missing EPS estimates by $0.79 and reporting revenue of $7.68 million against expectations of $86.32 million. Analysts have mixed ratings, with one sell, one hold, and nine buy ratings. CEO Michael A. Metzger and insider Neil Gallagher sold shares recently, reducing their stakes. Institutional investors have increased their holdings, with State Street Corp and Soleus Capital Management among the notable investors. The company has a market cap of $1.23 billion and is focused on cancer therapies.</p>

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 7.4% on Disappointing Earnings